FDA approval is just the beginning. Now Lilly’s Kisunla faces the tough Alzheimer’s market

If drugmakers have learned anything in the last few years about the Alzheimer’s market, it’s that an FDA approval is by no means a guarantee of success.

So as Eli Lilly celebrates last week’s green light for the amyloid-plaque clearing Kisunla — formerly known as donanemab — there’s still work to be done to ensure patients who qualify can access the drug.